Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
1. In this randomized controlled trial, baricitinib, a Janus kinase (JAK) inhibitor, preserved beta cell function and reduced insulin requirement compared to placebo in patients with new-onset type 1 diabetes mellitus (T1DM). 2. Patients receiving baricitinib also demonstrated tighter glycemic control compared to those receiving the placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: The
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia TARRYTOWN, N.Y., March 11, 2024 -- Regeneron Pharmaceuticals, Inc. announced the...
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH)...
1. In this randomized controlled trial, tenecteplase administered at 4.5 to 24 hours after stroke onset to patients with an occluded middle cerebral artery (MCA) or internal carotid artery (ICA) was not superior to placebo. 2. Tenecteplase did not differ from placebo with regards to rates of death and symptomatic intracranial hemorrhage. Evidence Rating Level:
1. In this randomized controlled trial, among patients with primary biliary cholangitis (PBC) who had had inadequate response to ursodeoxycholic acid, seladelpar was superior to placebo in achieving biochemical response and symptomatic management. 2. Seladelpar had an acceptable safety profile, with similar rates of adverse events to a placebo. Evidence Rating Level: 1 (Excellent) Study